Intravenous administration of iron dextran as a potential inducer for hemochromatosis: Development of an iron overload animal model
Narra J · 2024
DOI: 10.52225/narra.v4i3.1003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Narra J, 2024. Verfasst von Erick Khristian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral Program in Biotechnology, Postgraduate School, Universitas Padjadjaran, Bandung, Indonesia. Hauptthemen laut MEDLINE: Iron-Dextran Complex, Hemochromatosis, Iron Overload. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Iron overload in transfusion-dependent thalassemia patients represents a significant public health challenge due to its high mortality rate and risks of severe complications. Therefore, developing safe and effective therapeutic modalities for managing iron overload is critical, as current animal models inadequately replicate human conditions. The aim of this study was to investigate the effects of intravenous iron dextran on hepatocyte morphology, liver iron concentration, and serum iron profile changes as a model for hemochromatosis. An experimental design with a post-test-only control group method was conducted using animal models. Fifty rats were used and divided into ten groups, nine received different intravenous doses of iron dextran: 10, 20, 30, 40, 50, 60, 80, 100, and 120 mg/kg body weight (BW) and a control group received no treatment. The results showed that intravenous iron dextran starting at a dose of 10 mg/kg BW caused significant changes in liver iron concentration while starting at 20 mg/kg BW significantly affected hepatocyte morphology, transferrin levels, unsaturated iron binding capacity, serum iron levels, and transferrin saturation. Intravenous iron dextran starting at 40 mg/kg BW resulted significant changes in the level of total iron binding capacity compared to control group. In conclusion, intravenous iron dextran significantly altered hepatocyte morphology, increased liver iron concentration, and modified the serum iron profile, reflecting changes that might be observed in patients with transfusion-dependent thalassemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doctoral Program in Biotechnology, Postgraduate School, Universitas Padjadjaran, Bandung, Indonesia.
- Faculty of Health Science and Technology, Universitas Jenderal Achmad Yani, Cimahi, Indonesia.
- Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
- Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Jatinangor, Indonesia.
Zitieren
APA
Khristian, E., Ghozali, M., Bashari, M. H., Purnama, J. N., Irianto, G., Panigoro, R., & Safitri, R. (2024). Intravenous administration of iron dextran as a potential inducer for hemochromatosis: Development of an iron overload animal model. Narra J. https://doi.org/10.52225/narra.v4i3.1003
Vancouver
Khristian E, Ghozali M, Bashari MH, Purnama JN, Irianto G, Panigoro R, et al. Intravenous administration of iron dextran as a potential inducer for hemochromatosis: Development of an iron overload animal model. Narra J. 2024. doi:10.52225/narra.v4i3.1003
BibTeX
@article{Khristian2024,
author = {Khristian, Erick and Ghozali, Mohammad and Bashari, Muhammad H and Purnama, Jeri N and Irianto, Gunawan and Panigoro, Ramdan and Safitri, Ratu},
title = {Intravenous administration of iron dextran as a potential inducer for hemochromatosis: Development of an iron overload animal model},
journal = {Narra J},
year = {2024},
doi = {10.52225/narra.v4i3.1003}
}
EUVIMED